Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rifkin

Showing results (41-50 of 84) with videos related to

Pageof 9
Sort By:
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 1, 1996
Increased bcl-2 protein levels in prostatic adenocarcinomas are not associated with rearrangements in the 2.8 kb major breakpoint region or with p53 protein accumulationB V Kallakury, J Figge, B Leibovich, et al.
Bioinformatics (Oxford, England)|July 27, 2001
Molecular classification of multiple tumor typesC H Yeang, S Ramaswamy, P Tamayo, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 25, 2015
Connect MM Registry: The Importance of Establishing Baseline Disease CharacteristicsRobert M Rifkin, Rafat Abonour, Howard Terebelo, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 4, 2018
Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United StatesParameswaran Hari, Dorothy Romanus, Antonio Palumbo, et al.
American Journal of Hematology|May 26, 2017
Recognition of early mortality in multiple myeloma by a prediction matrixHoward Terebelo, Shankar Srinivasan, Mohit Narang, et al.
Investigational New Drugs|October 13, 2010
A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete responseRobert M Rifkin, Andrew Greenspan, John F Schwerkoske, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 22, 2019
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple MyelomaJatin Shah, Saad Usmani, Edward A Stadtmauer, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 10, 2017
Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating OutcomesJatin J Shah, Rafat Abonour, Christina Gasparetto, et al.
Retinal Cases & Brief Reports|May 14, 2021
CATASTROPHIC, BILATERAL RETINAL VASCULAR OCCLUSION AFTER INTRAVITREAL BEVACIZUMAB INJECTIONCaleb C Ng, Daniel Brill, Emmett T Cunningham, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 22, 2022
A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choicesRobert M Rifkin, Jeffrey Crawford, Reshma L Mahtani, et al.
Pageof 9

Showing results (41-50 of 84) with videos related to

Sort By:
Pageof 9
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 1, 1996
Increased bcl-2 protein levels in prostatic adenocarcinomas are not associated with rearrangements in the 2.8 kb major breakpoint region or with p53 protein accumulationB V Kallakury, J Figge, B Leibovich, et al.
Bioinformatics (Oxford, England)|July 27, 2001
Molecular classification of multiple tumor typesC H Yeang, S Ramaswamy, P Tamayo, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 25, 2015
Connect MM Registry: The Importance of Establishing Baseline Disease CharacteristicsRobert M Rifkin, Rafat Abonour, Howard Terebelo, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 4, 2018
Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United StatesParameswaran Hari, Dorothy Romanus, Antonio Palumbo, et al.
American Journal of Hematology|May 26, 2017
Recognition of early mortality in multiple myeloma by a prediction matrixHoward Terebelo, Shankar Srinivasan, Mohit Narang, et al.
Investigational New Drugs|October 13, 2010
A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete responseRobert M Rifkin, Andrew Greenspan, John F Schwerkoske, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 22, 2019
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple MyelomaJatin Shah, Saad Usmani, Edward A Stadtmauer, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 10, 2017
Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating OutcomesJatin J Shah, Rafat Abonour, Christina Gasparetto, et al.
Retinal Cases & Brief Reports|May 14, 2021
CATASTROPHIC, BILATERAL RETINAL VASCULAR OCCLUSION AFTER INTRAVITREAL BEVACIZUMAB INJECTIONCaleb C Ng, Daniel Brill, Emmett T Cunningham, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 22, 2022
A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choicesRobert M Rifkin, Jeffrey Crawford, Reshma L Mahtani, et al.
Pageof 9